Patients should inform their healthcare providers about any kidney disease, significant weight changes, or other medications they are taking, as these factors may influence both the therapeutic effects and elimination timeline of GLP-1 receptor agonists
6.6% with retatrutide 4 mg, 9 mg, 12 mg vs
Baseline HbA1c, fasting glucose, insulin levels, lipid profile, and inflammatory markers (CRP, GLP-1R signaling capacity) can contextualize treatment response potential and help your provider optimize dosing, duration, and monitoring protocols
Lipid improvements Retatrutide produces substantial improvements in lipid profiles
Diabetes Metab Res Rev 27(6):528542
You kick off your journey with a one-on-one evaluation via an online consultation with our competent healthcare providers